Monkey Tetanus Toxoid IgM ELISA Kit

Name: Monkey Tetanus Toxoid IgM ELISA Kit
SKU: DEIASL078
Rating: 5 (1 reviews)

Regulatory status: For research use only, not for use in diagnostic procedures.

COA

SDS

Datasheet

Summary

Sample

Serum, plasma

Species Reactivity

Monkey

Detection Method

Indirect-ELISA

Intended Use

This test kit allows rapid and quantitative measurement of antitetanus toxoid IgM levels in rhesus or cynomolgus monkey serum or plasma.

Contents of Kit

No.	Components	Size	Storage Conditions
1	Tetanus Toxoid Coated 96-well Plate	12 strips of 8 wells	2-8°C
2	Anti-Monkey IgM HRP Conjugate	11 mL	2-8°C
3	Standard Stock	1 vial	Store < -20°C
4	20× Wash Solution	50 mL	2-8°C
5	Diluent	30 mL	2-8°C
6	TMB Reagent	11 mL	2-8°C
7	Stop Solution (1N HCl)	11 mL	2-8°C

Storage

1. The reference standard should be stored at -20°C for optimal stability.
2. All remaining kit components should be stored at 2-8°C.
3. The microtiter plate should be kept in a sealed bag with desiccant to minimize exposure to damp air. Test kit will remain stable for six months from the date of purchase provided that the components are stored as described above.

General Description

Drug candidates are routinely screened for evidence of immune system regulation during the discovery process. It is important that the immune response is not enhanced or decreased since such effects may lead to hypersensitivity or increased susceptibility to infection. Determination of a drug candidate's effects on antitetanus toxoid antibody levels allows easy assessment of immune system regulation. Animals are immunized with tetanus toxoid while undergoing drug treatment and serum is collected at appropriate times post immunization. Serum collected 5-7 days after immunization is used for measurement of anti-tetanus toxoid IgM levels, and serum collected 14+ days post immunization is used to measure anti-tetanus toxoid IgG levels. Comparison of anti-tetanus toxoid IgG or IgM levels in drug treated versus control groups reveals effects on the immune response.

Standard Curve

A typical standard curve with optical density readings at 450nm on the Y-axis against anti-tetanus toxoid IgM concentrations on the Xaxis is shown below. This curve is for illustration only and should not be used to calculate unknowns. Each user should obtain his or her data and standard curve in each experiment.

Citations

Have you cited DEIASL078 in a publication? Let us know and earn a reward for your research.

Documents

pdf COA

pdf SDS

pdf Datasheet

Immunoassays for Process-related Impurities

QA & Reviews

Customer Reviews

References

Control selection and confounding factors: A lesson from a Japanese case-control study to examine acellular pertussis vaccine effectiveness

VACCINE

Authors: Ohfuji, Satoko; Okada, Kenji; Nakano, Takashi; Ito, Hiroaki; Hara, Megumi; Kuroki, Haruo; Hirota, Yoshio

Abstract

When using a case-control study design to examine vaccine effectiveness, both the selection of control subjects and the consideration of potential confounders must be the important issues to ensure accurate results. In this report, we described our experience from a case-control study conducted to evaluate the effectiveness of acellular pertussis vaccine combined with diphtheria-tetanus toxoids (DTaP vaccine). Newly diagnosed pertussis cases and age- and sex-matched friend-controls were enrolled, and the history of DTaP vaccination was compared between groups. Logistic regression models were used to calculate odds ratios (ORs) and 95% confidence intervals (CIs) of vaccination for development of pertussis. After adjustment for potential confounders, four doses of DTaP vaccination showed a lower OR for pediatrician-diagnosed pertussis (OR = 0.11, 95% CI, 0.01-0.99). In addition, the decreasing OR of four doses vaccination was more pronounced for laboratory-confirmed pertussis (OR = 0.07, 95%Cl, 0.01-0.82). Besides, positive association with pertussis was observed in subjects with a history of steroid treatment (OR = 5.67) and those with a recent contact with a lasting cough (OR = 4.12). When using a case-control study to evaluate the effectiveness of vaccines, particularly those for uncommon infectious diseases such as pertussis, the use of friend-controls may be optimal due to the fact that they shared a similar experience for exposure to the pathogen as the cases. In addition, to assess vaccine effectiveness as accurately as possible, the effects of confounding should be adequately controlled with a matching or analysis technique. (C) 2017 The Author(s). Published by Elsevier Ltd.

Detection of Anti-tetanus Toxoid Monoclonal Antibody by Using Modified Polycarbonate Surface

PLASMONICS

Authors: Raeisi, Salimeh; Molaeirad, Ahmad; Sadri, Minoo; Nejad, Hamideh Rouhani

Abstract

In recent years, CD surface modification methods are employed for immunoassay techniques that is called BioCD technology. In this research, first polycarbonate surface was activated with UV ozone and a hydrophilic surface was obtained. Contact angle measurements and atomic force microscopy technique confirmed the hydrophilic property of surface. After that, tetanus toxoid was immobilized on modified CD surface then specific monoclonal antibody, gold nanoparticles conjugated antibody, silver salt, and hydroquinone were added on modified CD surface. So a sandwiches complex as tetanus toxoid, tetanus toxoid monoclonal antibody, and gold nanoparticles conjugated antibody was obtained on CD surface. ATR result showed the immobilization of tetanus toxoid on modified CD surface. Localized surface plasmon resonance (LSPR) and DLS results confirmed the complex formation. Silver salt and hydroquinone were added for signal amplification. Detection limit of anti-tetanus toxoid IgG monoclonal antibody was obtained 0.005IU/ml by LSPR and DLS techniques. The presented method increases the assay's sensitivity. BioCD-based immunoassay for detection of anti-tetanus toxoid IgG monoclonal antibody could be applicable in development and fabrication of biomedical devices.